<DOC>
	<DOCNO>NCT02634853</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Tavilermide Ophthalmic Solution compare Placebo Ophthalmic Solution treat sign symptom dry eye .</brief_summary>
	<brief_title>A Safety Efficacy Study Tavilermide ( MIM-D3 ) Ophthalmic Solution Treatment Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be least 18 year age Provided write informed consent Have report history dry eye Have history use desire use eye drop dry eye Be diagnose ongoing ocular infection ( bacterial , viral , fungal ) , active ocular inflammation ( e.g . follicular conjunctivitis ) Visit 1 , diagnose ocular rosacea , viral bacterial disease cornea conjunctiva , within last 12 month Have plan ocular and/or lid surgery study period Have correct visual acuity great equal +0.7 assess Early Treatment Diabetic Retinopathy Study ( ETDRS ) scale eye Visit 1 Have uncontrolled systemic disease Be woman pregnant , nurse planning pregnancy Be woman childbearing potential use acceptable mean birth control ; acceptable method contraception include : hormonal oral , implantable , injectable , transdermal contraceptive ; mechanical spermicide conjunction barrier diaphragm condom ; IUD ; surgical sterilization partner . For nonsexually active female , abstinence may regard adequate method birth control ; however , subject becomes sexually active study , must agree use adequate birth control define remainder study Have know allergy and/or sensitivity test article component Have condition situation investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study Be currently enrol investigational drug device study use investigational drug device within 45 day Visit 1 Be unable unwilling follow instruction , include participation study assessment visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dry Eye</keyword>
</DOC>